## Compounded Tirzepatide in 2026 · MomsOnGLP1
Canonical: https://momsonglp1.org/compounded-tirzepatide-what-changed
Page modified: 2026-11-21T00:00:00.000Z

Where compounded tirzepatide stands as of November 2026: the FDA's shortage, 503A and 503B rules, safety questions to ask, and real price ranges.

Real moms, real GLP-1 talk Compounded Tirzepatide in 2026: What Changed and What I Would Ask Where compounded tirzepatide stands as of November 2026: the FDA's shortage, 503A and 503B rules, safety questions to ask, and real price ranges. Written by Jenna Marsh — editorial research, not medical advice November 2026 On this page The short answer What the shortage ending actually did The 2026 crackdown, in order The safety questions I would ask What it really costs How it differs from Zepbound and Mounjaro The short answer As of November 2026, compounded tirzepatide is still sold, but it sits on much narrower legal ground than it did in 2024. The FDA declared the tirzepatide shortage over in December 2024, and the extra room compounders had during the shortage has ended 1 . It is not FDA-approved, and the agency does not check it for safety, quality or effectiveness before it is sold 2 . I wrote a longer piece on compounded versus brand semaglutide a few weeks ago. This one is the tirzepatide version, because the rules moved again in 2026 and I wanted the dates in one place. What the shortage ending actually did While Zepbound and Mounjaro were officially short, compounders could make tirzepatide copies with little federal pushback. That window closed for outsourcing facilities on March 19, 2025, and for state-licensed pharmacies after a court case in 2025 1 . The FDA's April 2026 update says tirzepatide is not on its drug shortage list or on the list of bulk ingredients outsourcing facilities may use 1 . The two kinds of compounder now work under different limits: 503A pharmacy: fills a prescription for one named patient. It may not regularly make what are essentially copies of an approved drug, unless the prescriber documents a significant difference for that patient. The FDA says it does not plan to act on four or fewer such prescriptions in a calendar month 1 . 503B outsourcing facility: makes larger batches. It cannot make copies of an approved drug unless the drug is on the shortage list or the 503B bulks list 1 . That is why so much compounded tirzepatide is now sold with an added ingredient, a custom dose or a note about individual need. I can't judge whether any single product meets the rule, and a sales page can't prove it does. The 2026 crackdown, in order Three FDA moves this year are worth knowing by date. In February, the agency said it intends to restrict the GLP-1 ingredients used in unapproved compounded drugs, and that ads may not call compounded products generic versions of approved drugs or the same as them 3 . In March, it sent 30 warning letters to telehealth companies, mainly for implying their compounded drugs were the same as approved ones and for selling under their own brand without saying who actually compounded it 4 . In May, the FDA proposed keeping tirzepatide, semaglutide and liraglutide off the 503B bulks list for good, then extended the comment period in June 5 . When I checked the Federal Register in November 2026, I found no final decision. So the proposal is real, but it is still a proposal. The safety questions I would ask The FDA reports more than 730 adverse-event reports linked to compounded tirzepatide as of May 31, 2026, along with reports of prescribed doses above the approved label and fake products carrying the names of pharmacies that never made them 2 . Those reports don't prove the drug caused each problem, but they are reason enough to ask: Which pharmacy compounds it, and is it a 503A pharmacy or a 503B facility? What is the concentration, and how many units equal my dose in milligrams? What else is in the vial, and does the plan follow the approved tirzepatide dose ladder or something custom? Who answers if I'm not sure how much to draw up? Measuring from a vial is a different job from clicking a pen, which is why I also compared the Zepbound vial, KwikPen and autoinjector side by side. If the answers to those four questions live only in marketing copy, I would keep looking. What it really costs Across the 113 providers on this site that list a tirzepatide starting price, the middle half sits between $199 and $329 a month, with a median of $259. The spread inside that range is mostly billing terms rather than medicine, the same trap I described in what a GLP-1 costs without insurance . A four-week cycle bills thirteen times a year, not twelve. Some examples from the provider records I keep: SnagRx lists $119 a month at every dose, and Lttl lists $149 for a four-week supply on monthly billing. Sprout Health charges $199 every four weeks with no commitment, while bmiMD is $139 for one month and $109 a month only on a prepaid twelve-month plan. Strut Health also sells an oral tirzepatide lozenge at $199, even though no FDA-approved tirzepatide pill exists. I would compare the full term and the refund rules before signing anything. How it differs from Zepbound and Mounjaro Zepbound and Mounjaro are the same approved molecule under two names, one for weight and sleep apnea and one for type 2 diabetes, as I laid out in Zepbound versus Mounjaro . Both are made by Lilly, checked by the FDA and come in fixed doses. The brand price gap has also narrowed. Lilly lists the Zepbound KwikPen at $299 for 2.5 mg, $399 for 5 mg and $449 for higher doses when refills stay within its 45-day window 6 . At a typical maintenance dose, a cheap compounded month and a brand month can be closer than the ads suggest, and I would price both at that dose. If a compounded dose ever leaves you vomiting, unable to keep fluids down or worried you injected too much, call your prescriber or Poison Control at 1-800-222-1222, or go to urgent care. Okay, so which one? Skip the guesswork — compare providers side by side These boards sort providers by what usually matters most to a mom. Some are partners, and we may be paid if you sign up through our links. Cheapest The lowest honest monthly price I could find — teasers ignored, the all-in number ranked. Best for real life For when there's a toddler on your hip — nap-time-easy signup, no surprise bills. Fastest signup Who gets you from sign-up to a real price without dragging it out — by signup-ease score. Or go straight to the SnagRx review and the Lttl review , or compare any two head-to-head . Frequently asked questions Is compounded tirzepatide legal in 2026? It is still sold, but under narrower rules than during the shortage. As of November 2026, the FDA says tirzepatide is not on its shortage list or the 503B bulks list. A 503A pharmacy generally may not regularly make essentially copies of Zepbound or Mounjaro unless a prescriber documents a significant difference for the patient. Whether a specific product complies is not something a sales page can establish. Did the FDA ban compounded tirzepatide? Not outright, as of November 2026. In May 2026 the FDA proposed keeping tirzepatide off the list of bulk ingredients that 503B outsourcing facilities may use, and extended the comment period in June. No final decision appeared in the Federal Register when this page was checked in November 2026. How much does compounded tirzepatide cost? Across 113 providers with a listed tirzepatide starting price, the middle half sat between about $200 and $329 a month in November 2026, with a median of $259. Prices depend on billing terms, so compare the monthly price, the four-week versus calendar-month cycle and any prepayment requirement. Is compounded tirzepatide the same as Zepbound? No. Zepbound and Mounjaro are FDA-approved tirzepatide made by Lilly. Compounded tirzepatide is prepared by a pharmacy and is not reviewed by the FDA for safety, effectiveness or quality before sale. The FDA also says advertising may not describe a compounded product as a generic version of, or the same as, an approved drug. References U.S. Food and Drug Administration ( 2026 ). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize . U.S. Food and Drug Administration . https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize U.S. Food and Drug Administration ( 2026 ). FDA's concerns with unapproved GLP-1 drugs used for weight loss . U.S. Food and Drug Administration . https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss U.S. Food and Drug Administration ( 2026 ). FDA intends to take action against non-FDA-approved GLP-1 drugs . U.S. Food and Drug Administration . https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs U.S. Food and Drug Administration ( 2026 ). FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s . U.S. Food and Drug Administration . https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s U.S. Food and Drug Administration ( 2026 ). List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (notice proposing not to include semaglutide, tirzepatide and liraglutide) . Federal Register . its website Eli Lilly and Company ( 2026 ). Zepbound coverage and savings: self-pay pricing for the KwikPen and vial and purchase offer terms . Eli Lilly and Company . its website One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. Pregnancy planning and breastfeeding need advice for the exact medicine and formulation. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history. Continue reading Zepbound Vials vs KwikPen vs Autoinjector: The Format Question I Didn't Expect The Zepbound formats sold in November 2026 compared: how each injects, what it costs self-pay, Medicare coverage, storage for travel, and needle nerves. Read GLP-1 Coverage on Medicare and Medicaid: What I Would Check for My Mom Medicare's $50 GLP-1 Bridge, who qualifies, the heart and sleep-apnea routes through Part D, and why Medicaid depends on your state, as of November 2026. Read How Much Does a GLP-1 Actually Cost Without Insurance? (The Honest Number) The real monthly cost of GLP-1 without insurance — cheapest compounded semaglutide, brand vs compounded, membership fees, and the number that lasts. Read The Tirzepatide Dosing Schedule, Read the Way a Mom Would The Zepbound dose ladder from the FDA label, the missed-dose rule, the birth-control windows, and what compounded tirzepatide programs do differently. Read Zepbound vs Mounjaro: Same Drug, Two Names, One Big Difference Zepbound and Mounjaro are both tirzepatide. Why there are two names, and why which one you're prescribed changes what insurance does. Read Microdosing GLP-1s: The Honest Take on the Hype What low-dose GLP-1 marketing means, what dose-response trials can support, and the questions to ask about monitoring, cost and compounded products. Read

Sources:
- https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
- https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
- its website
- its website
